RayzeBio, Inc.
Overview
RayzeBio is focused on creating precision radiopharmaceutical therapies (RPTs) for patients living with cancer, leveraging an alpha-emitting isotope, actinium 225, in their drug development programs.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to RayzeBio, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.